Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HUMA | US
-0.40
-7.05%
Healthcare
Biotechnology
31/03/2024
05/07/2024
5.27
5.72
5.87
5.26
Humacyte Inc. engages in the development and manufacture of off-the-shelf implantable and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs which would target the vascular repair reconstruction and replacement market including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham North Carolina.
View LessLow Debt to Asset (< 0.2)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
104.6%1 month
105.9%3 months
109.9%6 months
108.4%-
-
25.41
0.71
0.11
-3.33
-
-
-93.57M
627.57M
627.57M
-
-
-
-100.00
-195.68
1.65
5.76
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.70
Range1M
3.27
Range3M
7.16
Rel. volume
0.96
Price X volume
15.95M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Praxis Precision Medicines Inc | PRAX | Biotechnology | 40.32 | 689.79M | 0.80% | n/a | 0.97% |
Stoke Therapeutics Inc | STOK | Biotechnology | 13.12 | 683.82M | 3.55% | n/a | 4.52% |
AnaptysBio Inc | ANAB | Biotechnology | 24.75 | 676.14M | -0.60% | n/a | 685.61% |
UroGen Pharma Ltd | URGN | Biotechnology | 15.88 | 653.15M | 5.80% | n/a | -246.69% |
Sage Therapeutics Inc | SAGE | Biotechnology | 10.78 | 648.76M | 1.51% | n/a | 0.47% |
Pliant Therapeutics Inc. | PLRX | Biotechnology | 10.52 | 634.63M | -0.57% | n/a | 12.50% |
Scholar Rock Holding Corporation | SRRK | Biotechnology | 7.74 | 617.30M | -0.39% | n/a | 32.90% |
Savara Inc | SVRA | Biotechnology | 4.43 | 612.18M | 2.31% | n/a | 21.80% |
GH Research PLC Ordinary Shares | GHRS | Biotechnology | 11.75 | 611.33M | -2.49% | n/a | 0.43% |
Lexicon Pharmaceuticals Inc | LXRX | Biotechnology | 1.67 | 603.69M | 0.60% | n/a | 36.78% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Latham Group Inc. | SWIM | Building Products & Equipment | 2.74 | 316.67M | -3.52% | 75.75 | 80.81% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.55 | 298.02M | -0.34% | 8.24 | 25.57% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 26.52 | 294.97M | -4.29% | 17.47 | -562.47% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 12.93 | 209.56M | -2.78% | 8.94 | 15.44% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.33 | -2.43 | Cheaper |
Ent. to Revenue | - | 4,101.76 | - |
PE Ratio | - | 41.26 | - |
Price to Book | 25.41 | 22.34 | Par |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 109.89 | 76.52 | Riskier |
Debt to Equity | 0.71 | 0.51 | Expensive |
Debt to Assets | 0.11 | 0.24 | Cheaper |
Market Cap | 627.57M | 3.77B | Emerging |